<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289549</url>
  </required_header>
  <id_info>
    <org_study_id>BCX1777-Bo-05-204</org_study_id>
    <nct_id>NCT00289549</nct_id>
  </id_info>
  <brief_title>Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>Phase II Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days
      each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour
      prior to or two hours after meals. Patients will be evaluated after 1 full cycle of therapy
      (28 days).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate after 2 cyclesof forodesine therapy.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>forodesine hydrochloride (BCX-1777)</intervention_name>
    <description>experimental, forodesine oral dose 200 mg administered daily.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 years and older

          -  Diagnosis of CLL established by peripheral blood and bone marrow examination and using
             the standard criteria

          -  Patients with Rai stage III or IV, or earlier stage with massive, symptomatic
             lymphadenopathy requiring therapy

          -  Primary resistance to fludarabine-based therapy (no complete response [CR] or partial
             response [PR]) or progressive disease within 6 months of response to prior fludarabine
             containing regimen.

          -  ECOG performance status of 0, 1, 2 or 3

          -  Willing to take adequate contraception (i.e. latex condom, cervical cap, diaphragm,
             abstinence, etc.) for the entire duration of the study and 3 months after

          -  All investigational treatments should have been discontinued for at least 1 week prior
             to the initiation of the study drug.

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Unable or unwilling to sign consent

          -  Severe, ongoing co-morbid conditions, which would preclude safe delivery of the
             investigational therapy

          -  Active serious infections that are not controlled by antibiotics

          -  ECOG performance status 4

          -  Inadequate renal function: creatinine 2.0 or more unless related to the disease

          -  Inadequate liver function: bilirubin 3.0 or more, transaminases 3 x upper limit of
             normal or more unless related to the disease

          -  Known positive test for HIV

          -  Patients with known hepatitis B and/or hepatitis C active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Ravandi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center, University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center, University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2006</study_first_submitted>
  <study_first_submitted_qc>February 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <disposition_first_submitted>January 19, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 19, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 23, 2012</disposition_first_posted>
  <last_update_submitted>February 6, 2012</last_update_submitted>
  <last_update_submitted_qc>February 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>leukemia</keyword>
  <keyword>Advanced, fludarabine-refractory CLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

